tradingkey.logo

Renovaro Inc

RENB
1.420USD
0.0000.00%
Handelsschluss 02/06, 16:00ETKurse um 15 Minuten verzögert
251.90MMarktkapitalisierung
VerlustKGV TTM

Renovaro Inc

1.420
0.0000.00%

mehr Informationen über Renovaro Inc Unternehmen

Lunai Bioworks, Inc., formerly Renovaro Inc., is focused on AI-powered biodefense, drug discovery and advanced diagnostics. The Company is engaged in harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities. From high-resolution phenotyping to predictive disease modeling, the Company is pioneering a new era of precision diagnostics-where early detection, patient stratification, and therapeutic targeting converge into a single, adaptive platform. These are designed to transform clinical decision-making, reduce time-to-treatment, and unlock previously inaccessible insights from biological data. Its proprietary platforms in translational analytics, in vivo modeling, and machine vision-accelerating biomarker discovery and therapeutic development in precision neurology and infectious disease.

Renovaro Inc Informationen

BörsenkürzelRENB
Name des UnternehmensLunai Bioworks Inc
IPO-datumNov 18, 2014
CEOWeinstein (David)
Anzahl der mitarbeiter- -
WertpapierartOrdinary Share
GeschäftsjahresendeNov 18
Addresse2080 Century Park East, Suite 906
StadtLOS ANGELES
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl90067
Telefon14539179840
Website
BörsenkürzelRENB
IPO-datumNov 18, 2014
CEOWeinstein (David)

Führungskräfte von Renovaro Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Douglas W. Calder
Mr. Douglas W. Calder
Independent Director
Independent Director
--
--
Mr. James A. Mcnulty, CPA
Mr. James A. Mcnulty, CPA
Independent Director
Independent Director
--
--
Mr. Mark Anthony Collins, Ph.D.
Mr. Mark Anthony Collins, Ph.D.
Independent Director
Independent Director
--
--
Mr. David Weinstein
Mr. David Weinstein
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Chris Tyson
Mr. Chris Tyson
Executive Vice President - Investor Relations
Executive Vice President - Investor Relations
--
--
Mr. Nathen Fuentes, CPA
Mr. Nathen Fuentes, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Douglas W. Calder
Mr. Douglas W. Calder
Independent Director
Independent Director
--
--
Mr. James A. Mcnulty, CPA
Mr. James A. Mcnulty, CPA
Independent Director
Independent Director
--
--
Mr. Mark Anthony Collins, Ph.D.
Mr. Mark Anthony Collins, Ph.D.
Independent Director
Independent Director
--
--
Mr. David Weinstein
Mr. David Weinstein
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Chris Tyson
Mr. Chris Tyson
Executive Vice President - Investor Relations
Executive Vice President - Investor Relations
--
--
Mr. Nathen Fuentes, CPA
Mr. Nathen Fuentes, CPA
Chief Financial Officer
Chief Financial Officer
--
--

Umsatzaufteilung

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Aktionärsstatistik

Aktualisiert: Mon, Feb 2
Aktualisiert: Mon, Feb 2
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
RS Group ApS
15.10%
Lakysa Ventures, Inc
9.67%
PasecoApS
6.17%
Gumrukcu (Serhat)
5.35%
The Vanguard Group, Inc.
2.12%
Andere
61.59%
Aktionäre
Aktionäre
Anteil
RS Group ApS
15.10%
Lakysa Ventures, Inc
9.67%
PasecoApS
6.17%
Gumrukcu (Serhat)
5.35%
The Vanguard Group, Inc.
2.12%
Andere
61.59%
Aktionärstypen
Aktionäre
Anteil
Corporation
31.30%
Individual Investor
8.09%
Investment Advisor
2.88%
Hedge Fund
1.12%
Investment Advisor/Hedge Fund
0.78%
Research Firm
0.03%
Andere
55.79%

Institutionelle Beteiligung

Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
145
2.48M
10.61%
+647.45K
2025Q3
144
2.83M
12.20%
+559.32K
2025Q2
156
65.41M
35.65%
+4.54M
2025Q1
161
103.48M
60.94%
+42.30M
2024Q4
155
103.71M
63.86%
+49.62M
2024Q3
149
51.49M
35.21%
-1.80M
2024Q2
151
51.88M
36.43%
+6.39M
2024Q1
154
44.98M
32.23%
+3.81M
2023Q4
151
44.01M
67.51%
+217.77K
2023Q3
146
41.12M
71.08%
+1.11M
Mehr Anzeigen

Aktionärsaktivitäten

Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
RS Group ApS
3.54M
15.1%
+1.86M
+110.33%
Oct 03, 2025
Lakysa Ventures, Inc
2.27M
9.67%
+116.68K
+5.43%
Oct 03, 2025
PasecoApS
1.45M
6.17%
-1.25M
-46.44%
Oct 03, 2025
Gumrukcu (Serhat)
1.25M
5.35%
--
--
Dec 05, 2025
The Vanguard Group, Inc.
517.63K
2.21%
+25.16K
+5.11%
Sep 30, 2025
William (Anderson Wittekind)
476.63K
2.03%
--
--
Dec 05, 2025
Millennium Management LLC
202.63K
0.86%
-12.33K
-5.74%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
127.28K
0.54%
-129.27K
-50.39%
Sep 30, 2025
Geode Capital Management, L.L.C.
126.54K
0.54%
+24.95K
+24.56%
Sep 30, 2025
Weinstein (David Hershel)
105.00K
0.45%
+20.00K
+23.53%
Oct 03, 2025
Mehr Anzeigen

Verbundene ETFs

Aktualisiert: Tue, Dec 2
Aktualisiert: Tue, Dec 2
Name
Anteil
iShares Russell 2000 Growth ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
0%
Global X Russell 2000 ETF
0%
Dimensional US Core Equity 1 ETF
0%
Proshares Ultra Russell 2000
0%
iShares Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 Value ETF
0%
iShares Russell 2000 Growth ETF
Anteil0%
Avantis US Small Cap Equity ETF
Anteil0%
iShares Micro-Cap ETF
Anteil0%
Global X Russell 2000 ETF
Anteil0%
Dimensional US Core Equity 1 ETF
Anteil0%
Proshares Ultra Russell 2000
Anteil0%
iShares Russell 2000 ETF
Anteil0%
ProShares UltraPro Russell2000
Anteil0%
ProShares Hedge Replication ETF
Anteil0%
iShares Russell 2000 Value ETF
Anteil0%

Dividende

In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten

Aktien-Split

Datum
Ex-Dividendentag
Art
Verhältnis
Sep 24, 2025
Merger
10→1
Datum
Ex-Dividendentag
Art
Verhältnis
Sep 24, 2025
Merger
10→1
KeyAI